Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2020

View Archived Issues

PDAC subtypes point to targeting strategies

Natural killer cells dabble in adaptive immunity

Novel inhaled therapy shows efficacy in preclinical models of SARS-CoV-2 virus infection

FDA grants approval to initiate COVID-19 study of EB-05

First patient dosed in phase IIa study of ATI-1777

European researchers patent new compounds for epilepsy

AstraZeneca discloses new PROTACs for cancer therapy

Protecting telomeres prevents lung fibrosis

First-in-human data presented for ASP-5354

Chiesi Farmaceutici identifies PI3K inhibitors

New IRAK-4 inhibitors synthesized by Galapagos

University of Pennsylvania divulges new CAR T cells for cancer

Apellis reports 18-month data on pegcetacoplan in advanced geographic atrophy

Second phase II study of Lyme disease vaccine candidate VLA-15 meets endpoints

Cardiff Oncology reports phase II results with onvansertib in mCRPC

Amicus presents interim phase I/II data for AT-GTX-501 gene therapy

COMPneo predicts carotid artery stenosis

PRISM3 study of CP-101 oral microbiome drug shows it prevents CDI recurrence

Phase IIb study in Japan of KW-6356 for Parkinson's disease meets primary endpoint

FDA grants full approval to Venclexta combinations for newly diagnosed AML

Union to explore use of UNI-91103 to prevent COVID-19

Nascent reports in vitro data on pritumumab for COVID-19

CRISPR Therapeutics reports topline phase I data on CTX-110 for relapsed or refractory NHL

IntraBio reports further data on IB-1001 for Niemann-Pick disease type C

Phase III data reported on Merck & Co.'s 15-valent pneumococcal conjugate vaccine V-114